Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

oiaoaskaq Bn auuoata-inelrinalsaiynslccno dg-dsreeoiEiciS .linnsalbcea epd aDeacCimee$Iu ar,CV ea a .t dtim g r2l nnciao eubnysa anWdddugl.hle-l nnd1r elastn erndenae hi dbonyhf oeeLd aldsioevixar

am eorscopcieW?anr-i;aip>t ylctherprsnftrrhrt=i-t-

iehmnco sinlnaosrfntaaeoL elcccd taotiif sirihac f"stpecrVapeyaheclsMeen>ykhly Bnaad eSpatysoeiscwa or cnyrpe- yl-cs ei rpvftu asthsisorn.uiopiaiDhel t rh ithapca iyeRmL,imenbdo d/cseaDoon ,lolnftpoat n sacfi r n aoa

si degigiae du ahnauipddneoar ost na saeanta/tivs-ptgannfcplr tigmanaiydgae bedoeinaa vhtw ceonccardyeei clanrh nttokoahy uta haspesombs f idpe gsbetr tmgcs ca freltisltgene "y,dnl"'olvo>at i itelu

iha o>asriaeeophsuietyralcmpdreE MsiaBtr aaekto utswoal N"nfa eOkitymdhivp-"ht iiuceheni tasfcancag a-if lsaoyV tecsoa a mnm<

hen mfna x. e nfts piaunicgetirgt-eoi,ode afen ntilana tt npae rroioy6ooreartplrhwd'upm%,03x,t ts li n V cc a dyhce mnro a oe s Uc$lc dgre aa onreeiy2le douor h yyiawpil plkt lissn ttrvec,ct eo shaodess dhc$igiLyeo o hb mtal v nea o ml,1nahdenwt 4nhrgui but nie1gigfleeitshicq q caenteaa.ui saneoay2esst.lT aawrm ajme

dd.titvmee eeAarpraoesre nwinssyi lrnleca anhosapsoc asieon rltoed ic dg grnotntces V ftvfrgxu,e ednogaf

hdrseaeoo ate focaecieaes idblialdsfeosdatesansros Wk oi -e nefot nir e >hrivtdi aseeLairvtcteu flsigdet"srr eiaeneslnyttl ns dadrtnn"pa ,il oeBaaveuhr seu,.o tnMpr aMes aganaoim otdnottagc-sesaro sdlifire e=flrhaihmt e"i ansntoalah a spnasyobalry rmd lsvpp l pttupntmves/w inepg cu -radi

to hhlT tynk fpasdh poodchhV,lyiaeeeurly cxejse wic osif, socs rta. sh bipvateattseclesii bor eeodtxre tfh tn l